Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.
Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.
复制标题
DOI：
10.3389/fneur.2018.00174
复制
发表时间：
2018
影响因子：
3.4
通讯作者：
Montalban X
中科院分区：
文献类型：
--
作者：
Saposnik G;Montalban X
多发性硬化症（MS）治疗的前景在不断变化。与这些疗法相关的疗效和风险存在显著异质性。因此，临床医生面临的挑战是根据几个因素（疾病活动水平、进展风险、个体患者偏好和特征、个人专业知识等）定制治疗，以确定安全性和有效性之间的最佳平衡。然而，大多数临床医生在决策和风险管理方面的正规培训有限。总之，这些因素可能导致治疗惰性（TI）;定义为当治疗目标未达到时，没有开始或加强治疗。TI可能导致次优治疗选择、更差的临床结局和更多的残疾。本文提供了一个简明扼要的概述影响TI在MS护理的因素。
The landscape of multiple sclerosis (MS) treatment is constantly changing. Significant heterogeneity exists in the efficacy and risks associated with these therapies. Therefore, clinicians have the challenge to tailor treatment based on several factors (disease activity level, risk of progression, individual patient preferences and characteristics, personal expertise, etc.), to identify the optimal balance between safety and efficacy. However, most clinicians have limited education in decision-making and formal training in risk management. Together, these factors may lead to therapeutic inertia (TI); defined as the absence of treatment initiation or intensification when therapeutic goals are unmet. TI may lead to suboptimal treatments choices, worse clinical outcomes, and more disability. This article provides a succinct overview on factors influencing TI in MS care.
登录
查看更多内容
影响因子：
7.6
作者：
Iyengar, SS;Lepper, MR
通讯作者：
Lepper, MR
影响因子：
120.7
作者：
Mamede, Silvia;van Gog, Tamara;Schmidt, Henk G.
通讯作者：
Schmidt, Henk G.
影响因子：
5.8
作者：
Prosperini, Luca;Gianni, Costanza;Gasperini, Claudio
通讯作者：
Gasperini, Claudio
影响因子：
6.1
作者：
KAHNEMAN, D;TVERSKY, A
通讯作者：
TVERSKY, A
影响因子：
8.3
作者：
Okonofua, EC;Simpson, KN;Egan, BM
通讯作者：
Egan, BM